MedTrace Logo

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

NCT05200429 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-01-20

No results posted yet for this study

Summary

This observational study intends to investigate health trends and data in cystic fibrosis patients all across Canada that are receiving modulator treatment so researchers can determine if CFTR treatments are effective over a long period of time and if so, which treatments work best for each individual. The study will collect clinical data from routine standard of care, patient reported outcomes via survey data and samples for a biobank.

Conditions

Interventions

DRUG

Trikafta

Highly Effective CFTR Modulator Therapy

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jonathan Rayment, MDCM · University of British Columbia

  • Bradley Quon, MD · University of British Columbia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200429 on ClinicalTrials.gov